ProPhase Labs (PRPH) Stock Price, News & Analysis

Company Overview

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.24 to $0.48
• 52-Week Range: $0.22 to $5.62
• Volume: 346,955 shs
• Average Volume: 2.66 million shs
• Market Capitalization: $13.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRPH Stock Analysis - Frequently Asked Questions

How have PRPH shares performed this year?

ProPhase Labs' stock was trading at $0.7571 at the beginning of 2025. Since then, PRPH stock has decreased by 56.3% and is now trading at $0.3307.
View the best growth stocks for 2025 here.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.21. The firm earned $3.63 million during the quarter, compared to the consensus estimate of $9.86 million. ProPhase Labs had a negative trailing twelve-month return on equity of 62.92% and a negative net margin of 217.64%.
Read the conference call transcript.

Who are ProPhase Labs' major shareholders?

Top institutional shareholders of ProPhase Labs include Cerity Partners LLC (0.22%) and Chapin Davis Inc. (0.19%).
View institutional ownership trends.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 5/04/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRPH
• CIK: 868278
• Web: www.prophaselabs.com
• Phone: (215) 345-0919
• Fax: 215-345-5920
• Employees: 130
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,780,000.00
• Net Margins: -217.64%
• Pretax Margin: -298.21%
• Return on Equity: -62.92%
• Return on Assets: -30.22%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 1.47
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $6.77 million
• Price / Sales: 2.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.74 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 41,879,000
• Free Float: 18,932,000
• Market Cap: $13.85 million
• Optionable: Optionable
• Beta: -0.56